University of California San Francisco
Helen Diller Family Comprehensive Cancer Center
Henry F. VanBrocklin, PhD

Henry F. VanBrocklin, PhD

Professor, Department of Radiology, and Director of Radiopharmaceutical Research, UCSF

Cancer Center Program Memberships

Experimental Therapeutics

Research Summary

I have over 25 years’ experience with the preparation and application of radiopharmaceuticals. I have developed several imaging agents targeting cell surface proteins (receptors, enzymes and transporters) including receptor-based imaging agents for hormone receptors, growth factor receptors, neuroreceptors, and prostate-specific membrane antigen. I have developed imaging agents for cardiac blood flow and metabolism. These imaging agents have included a broad range of molecular motifs from small molecules, antibodies, antibody fragments (e.g., Fabs, scFv, and diabodies), and aptamers, to proteins and peptides. These molecules have been labeled with a variety of isotopes for PET and SPECT imaging. As part of the development of these imaging agents, I have been engaged in the evaluation and validation of the tracer mechanism of localization and retention at the target site. I have prepared several in vitro and in vivo model systems and interpreted the data collected from these systems to determine the utility of the probes. I have successfully translated many of these tracers into humans. I have helped to write and secure several INDs for first-in-human tracer studies.
Over the last 10 years, I have been working on the development of PSMA targeting prostate cancer imaging agents in collaboration with Dr. Clifford Berkman at Washington State University. I am currently PI on a DoD PCRP-funded proposal to prepare these agents for human imaging studies. I am also UCSF PI on an NIH SBIR funded to perform the first-in-man PET/MRI imaging studies. I am currently also evaluating a new agent to measure T cell activation, 18F-FAraG. The pharmacokinetics of agent has been assessed in normal human subjects and will be further evaluated following immunotherapy response.

Education

Rensselaer Polytechnic Institute, Troy, NY, B.S., 1984, Chemistry
Rensselaer Polytechnic Institute, Troy, NY, M.S., 1986, Nuclear Chemistry
Washington University, St. Louis, MO, M.A., 1988, Nuclear Chemistry
Washington University, St. Louis, MO, Ph.D., 1990, Radiopharm. Chemistry
University of Illinois, Urbana, IL, Postdoctoral, 1992, Radiopharm. Chemistry


Professional Experience

  • 1990-1992
    DOE Alexander Hollaender Distinguished Postdoctoral Fellow, University of Illinois
  • 1992-present
    Chief Chemist, Head, Radiochemistry, Center for Functional Imaging, Lawrence Berkeley National Laboratory
  • 1992-2005
    Assistant Adjunct Professor of Radiology, University of California San Francisco
  • 2005-present
    Professor of Radiology, University of California San Francisco
  • 2005-present
    Joint Faculty Scientist, Department of Functional Imaging, LBNL

Honors & Awards

  • 1990-1992
    DOE Alexander Hollaender Distinguished Postdoctoral Fellowship
    Lawrence Berkeley National Laboratory Outstanding Performance Award (1993, 1997, 1998, 2000)
  • 2006
    SNM President's Distinguished Service Award

Selected Publications

  1. Taglang C, Korenchan DE, von Morze C, Yu J, Najac C, Wang S, Blecha JE, Subramaniam S, Bok R, VanBrocklin HF, Vigneron DB, Ronen SM, Sriram R, Kurhanewicz J, Wilson DM, Flavell RR. Late-stage deuteration of 13C-enriched substrates for T1 prolongation in hyperpolarized 13C MRI. Chem Commun (Camb). 2018 May 17; 54(41):5233-5236.
    View on PubMed
  2. Jordan CD, Han M, Kondapavulur S, Vera DB, Neumann KD, Moore T, Stillson C, Krug R, Behr S, Seo Y, VanBrocklin HF, Larson PEZ, Wilson M, Martin AJ, Hetts SW. Quantification of 89 Zr-Iron oxide nanoparticle biodistribution using PET-MR and ultrashort TE sequences. J Magn Reson Imaging. 2018 May 14.
    View on PubMed
  3. Mutch CA, Ordonez AA, Qin H, Parker M, Bambarger LE, Villanueva-Meyer JE, Blecha J, Carroll V, Taglang C, Flavell R, Sriram R, VanBrocklin H, Rosenberg O, Ohliger MA, Jain SK, Neumann KD, Wilson DM. [11C]Para-Aminobenzoic Acid: A Positron Emission Tomography Tracer Targeting Bacteria-Specific Metabolism. ACS Infect Dis. 2018 May 08.
    View on PubMed
  4. Neumann KD, Villanueva-Meyer JE, Mutch CA, Flavell RR, Blecha JE, Kwak T, Sriram R, VanBrocklin HF, Rosenberg OS, Ohliger MA, Wilson DM. Imaging Active Infection in vivo Using D-Amino Acid Derived PET Radiotracers. Sci Rep. 2017 Aug 11; 7(1):7903.
    View on PubMed
  5. Ronald JA, Kim BS, Gowrishankar G, Namavari M, Alam IS, D'Souza A, Nishikii H, Chuang HY, Ilovich O, Lin CF, Reeves R, Shuhendler A, Hoehne A, Chan CT, Baker J, Yaghoubi SS, VanBrocklin HF, Hawkins R, Franc BL, Jivan S, Slater JB, Verdin EF, Gao KT, Benjamin J, Negrin R, Gambhir SS. A PET Imaging Strategy to Visualize Activated T Cells in Acute Graft-versus-Host Disease Elicited by Allogenic Hematopoietic Cell Transplant. Cancer Res. 2017 06 01; 77(11):2893-2902.
    View on PubMed
  6. Neumann KD, Thompson CM, Blecha JE, Gerdes JM, VanBrocklin HF. An improved radiosynthesis of O-(2-[18 F]fluoroethyl)-O-(p-nitrophenyl)methylphosphonate: A first-in-class cholinesterase PET tracer. J Labelled Comp Radiopharm. 2017 Jun 15; 60(7):337-342.
    View on PubMed
  7. Blecha JE, Henderson BD, Hockley BG, VanBrocklin HF, Zubieta JK, DaSilva AF, Kilbourn MR, Koeppe RA, Scott PJH, Shao X. An updated synthesis of [11 C]carfentanil for positron emission tomography (PET) imaging of the µ-opioid receptor. J Labelled Comp Radiopharm. 2017 Jun 30; 60(8):375-380.
    View on PubMed
  8. Franc BL, Goth S, MacKenzie J, Li X, Blecha J, Lam T, Jivan S, Hawkins RA, VanBrocklin H. In Vivo PET Imaging of the Activated Immune Environment in a Small Animal Model of Inflammatory Arthritis. Mol Imaging. 2017 Jan 01; 16:1536012117712638.
    View on PubMed
  9. Kondapavulur S, Cote AM, Neumann KD, Jordan CD, McCoy D, Mabray MC, Liu D, Sze CH, Gautam A, VanBrocklin HF, Wilson M, Hetts SW. Optimization of an endovascular magnetic filter for maximized capture of magnetic nanoparticles. Biomed Microdevices. 2016 12; 18(6):109.
    View on PubMed
  10. Dannoon S, Ganguly T, Cahaya H, Geruntho JJ, Galliher MS, Beyer SK, Choy CJ, Hopkins MR, Regan M, Blecha JE, Skultetyova L, Drake CR, Jivan S, Barinka C, Jones EF, Berkman CE, VanBrocklin HF. Structure-Activity Relationship of (18)F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer. J Med Chem. 2016 06 23; 59(12):5684-94.
    View on PubMed
  11. Schankin CJ, Maniyar FH, Seo Y, Kori S, Eller M, Chou DE, Blecha J, Murphy ST, Hawkins RA, Sprenger T, VanBrocklin HF, Goadsby PJ. Ictal lack of binding to brain parenchyma suggests integrity of the blood-brain barrier for 11C-dihydroergotamine during glyceryl trinitrate-induced migraine. Brain. 2016 07; 139(Pt 7):1994-2001.
    View on PubMed
  12. Drake CR, Sevillano N, Truillet C, Craik CS, VanBrocklin HF, Evans MJ. Site-Specific Radiofluorination of Biomolecules with 8-[(18)F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chem Biol. 2016 06 17; 11(6):1587-94.
    View on PubMed
  13. Flavell RR, Truillet C, Regan MK, Ganguly T, Blecha JE, Kurhanewicz J, VanBrocklin HF, Keshari KR, Chang CJ, Evans MJ, Wilson DM. Caged [(18)F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjug Chem. 2016 Jan 20; 27(1):170-8.
    View on PubMed
  14. Page MJ, Lourenço AL, David T, LeBeau AM, Cattaruzza F, Castro HC, VanBrocklin HF, Coughlin SR, Craik CS. Non-invasive imaging and cellular tracking of pulmonary emboli by near-infrared fluorescence and positron-emission tomography. Nat Commun. 2015 Oct 01; 6:8448.
    View on PubMed
  15. Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, Aparici CM, Yee J, Bergsland E. Simultaneous (68)Ga-DOTA-TOC PET/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015 Aug; 40(6):1432-40.
    View on PubMed
  16. Ganguly T, Dannoon S, Hopkins MR, Murphy S, Cahaya H, Blecha JE, Jivan S, Drake CR, Barinka C, Jones EF, VanBrocklin HF, Berkman CE. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer. Nucl Med Biol. 2015 Oct; 42(10):780-7.
    View on PubMed
  17. Hope TA, Aggarwal R, Simko JP, VanBrocklin HF, Ryan CJ. Somatostatin imaging of neuroendocrine-differentiated prostate cancer. Clin Nucl Med. 2015 Jun; 40(6):540-1.
    View on PubMed
  18. Ley CR, Beattie NR, Dannoon S, Regan M, VanBrocklin H, Berkman CE. Synthesis and evaluation of constrained phosphoramidate inhibitors of prostate-specific membrane antigen. Bioorg Med Chem Lett. 2015 Jun 15; 25(12):2536-9.
    View on PubMed
  19. LeBeau AM, Sevillano N, Markham K, Winter MB, Murphy ST, Hostetter DR, West J, Lowman H, Craik CS, VanBrocklin HF. Imaging active urokinase plasminogen activator in prostate cancer. Cancer Res. 2015 Apr 01; 75(7):1225-35.
    View on PubMed
  20. Carroll V, Michel BW, Blecha J, VanBrocklin H, Keshari K, Wilson D, Chang CJ. A boronate-caged [¹8F]FLT probe for hydrogen peroxide detection using positron emission tomography. J Am Chem Soc. 2014 Oct 22; 136(42):14742-5.
    View on PubMed

Go to UCSF Profiles, powered by CTSI